Bharat Biotech, the leading COVID-19 vaccine candidates maker from India has said on Tuesday it is involved in recruitment of volunteers for a late-stage trial of the shot and half of the recruitment is done. The vaccine candidate maker has signed up 13,000 volunteers for the Phase 3 trial, backed by India's government medical research body, and is progressing towards its goal of 26,000, the company said.
Across various sites in India the trial began in mid-November. With the recruitment and the ongoing trial, Covaxin is on track to continue its progress towards achieving the goal for Phase-3 clinical trials across multiple sites in India. The indigenously developed 'Covaxin' COVID-19 vaccine has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV), it added. The vaccine is developed and manufactured at Bharat Biotech's BSL-3, biocontainment facility.
Bharat Biotech said, "Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses". Bharat Biotech Joint MD Suchitra Ella said, "This is an unprecedented vaccine trial ever to take place in India, and we are overwhelmed with the steady rise in participation".
Taking Covid 19 Jab is voluntary, Centre
8 passengers from UK tested Covid 19 positive at 3 Int. airports, amid Covid 19 new variant fear
